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ABSTRACT 
Menopause (MP) is a natural physiological event of woman’s life and is defined as the absence of menstrual periods for at least twelve months and 
loss of function of ovarian. The common symptoms of MP are irregular vaginal bleeding, hot flushes especially in head and chest, night sweats, 
insomnia, vaginal and urinary symptoms, cognitive dysfunction, increased cancer risk, osteopenia, high blood pressure, diabetes, and cardiovascular 
diseases. Microbiome has been associated with several health benefits. Probiotic supplementation helps to enhance the quality of microbiome 
thereby confers the health benefits to the host system. The microbiome, hormone (estrogen) changes, and probiotic intervention are related to the 
health status of the female reproductive system. The vaginal microbiome (VM) play a critical role in female reproductive health and MP, which can 
be greatly influenced by probiotics, and other medicine especially antibiotics and hormone therapy. The role of VM in supporting vaginal health is 
not clear and debatable. Understanding the role of vaginal Lactobacillus could expose the pathogenesis of vaginal dysbiosis, which helps to improve 
diagnostic and therapeutic strategies for several dysbiosis associated health issues and menopause-related symptoms. Recent studies suggested 
that the intervention of probiotic preparation with or without nutraceutical formulation (mostly with isoflavones) improve the health status of 
menopausal women. The mechanism of probiotics mediated health improvement in menopausal women is not yet described clearly. Several 
controversies are there on the link between probiotic, gut microbiota, vaginal microbiota, and estrogen deficit. The present review summarizes the 
influence of probiotic supplementation on climacteric symptoms in menopausal women. The literature search was made in Scopus, Google Scholar, 
PubMed using the keywords “probiotics” and “menopause”. The documents were carefully checked for the relevance to the current manuscript, and 
the selection was made without any restriction in the year of publication. 
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Menopause (MP) is a natural physiological event of woman’s life and 
is defined as the absence of menstrual periods for at least twelve 
months and loss of function of ovarian. MP is not a rapid biological 
event but is a relatively slow biological process. The age of MP varies 
(46-52 y) among the people, which greatly depends on the 
socioeconomic status, personal health care, and food habits. There is 
no unswerving test to predict the onset of MP. Moreover, MP can’t be 
predictable with the time of initial mensural period. The symptoms 
and the experience of the perimenopausal transition period differ 
for each woman [1, 2]. 
The common symptoms of MP are irregular vaginal bleeding, hot 
flushes especially in head and chest (about 85% of woman 
experiencing the hot flushes), night sweats, insomnia, vaginal 
symptoms (dryness, irritation, dyspareunia, and infections), urinary 
symptoms (frequent urination, urinary incontinence), cognitive 
dysfunction, physical changes, restlessness, muscle and joint pain, 
and MP also associated with increased cancer risk, osteopenia, high 
blood pressure, diabetes, and cardiovascular diseases. The 
symptoms are not common to all woman. Some people do not feel 
any or some of the symptoms during their MP [3-5]. 
The hormone changes or deficiency is the main cause of MP. Thus, 
hormone replacement therapy (HRT) is the primary treatment 
method to nullify or reduce the MP symptoms and to prevent the 
development of heart diseases and osteoporosis. The mode of 
administration, dose, and combination of the hormone are the key 
factors that affect the efficiency of the treatment and help to reduce 
the adverse side effects. Oral administration therapy was less 
effective compared to transdermal estrogen therapy [5]. 
Though HRT has beneficial effects, some of the controversial side 
effects were reported. The contentious HRT increased the risk of 
cancer development, thromboembolism, and cardiovascular 
consequences. There was no general treatment procedure, and HRT 
should be customized for each woman [6-8]. Moreover, many 
women seek alternative treatments other than HRT, when there are 
several health risks and uncertainty on reported benefits of HRT [6]. 
The serotonin-norepinephrine reuptake inhibitor and selective 
serotonin reuptake inhibitor were used to treat the hot flushes. These 
inhibitors help to improve vasomotor symptoms and sleep quality [9]. 
The phytoestrogens (PE) are phenolic compounds present in plants with 
mammalian estrogenic activity. PE binds to estrogen receptors and 
endorses either agonist or antagonist functions [10].  
Probiotics are living microbes when administered in an adequate 
amount, confers beneficial effects in the host health. Commonly, 
lactic acid bacteria (LAB) are considered as probiotics, and 
beneficial impact of the probiotics is highly associated with an 
individual’s health status, age, and lifestyle [11]. Probiotic strains 
were reported for several health aids and applications [11-23]. 
Changes in the gut microbiome influence the several physiological 
and biological process. The microbiome changes during estrogen 
deficiency, characteristics of MP, critically affects the MP symptoms 
and facilitates the development of illness like inflammatory diseases. 
The supplementation of probiotics significantly influences the gut 
microbiome of an individual [24]. 
Since the alternative therapies for MP with phytoestrogen and herbal 
products have been detailed previously by Borrelli and Ernst [25]. The 
current review narrates the probiotic based alternative treatment for MP 
and its impact on climacteric symptoms of menopausal women. The 
literature search was made in Scopus, Google Scholar, PubMed using the 
keywords “probiotics” and “menopause”. The documents were carefully 
checked for the relevance to the current review, and the selection was 
made without any restriction in the year of publication. 
Microbiome of women 
The microbiome is unique for every individual to some extent. The 
gut microbiome plays an essential role in almost all biological events 
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and cognitive functions. Subsequently, microbiome might possibly 
have a role in making healthy offspring moreover in persuading the 
general health status of an individual. The microbiome of a woman 
differs from man. The vaginal microbiome (VM) is influenced by 
several factors like menses, vaginal discharge, and sperm. VM 
greatly influences the health status of offspring. Lactobacillus spp. 
(especially Lactobacillus crispatus, L. gasseri, L. iners, and L. jensenii) 
are the dominant bacterial species present in VM of healthy women, 
and any alteration in the composition of VM leads to several adverse 
conditions like preterm birth, infertility, inflammatory and high risk 
of sexually transmitted diseases. Finally, it affects the quality of life 
[26-28]. Atopobium, Prevotella, Peptoniphilus, Dialister, Megasphaera, 
Gardnerella are some of the leading non-Lactobacillus microbial 
community residing in the urogenital tract of women [26].  
The role of VM in sustaining vaginal health is not clear and 
controversial. Understanding the role of vaginal Lactobacillus could 
uncover the pathogenesis of vaginal dysbiosis, which helps to refine 
diagnostic and therapeutic strategies for several dysbiosis 
associated health issues and to diminish or manage the menopause-
related symptoms [29]. 
The VM composition differs in post-menopausal women when 
compared with premenopausal women, particularity the Lactobacillus 
content. The VM is extremely affected by the HRT [30-32]. Menopause 
decreases a load of Lactobacillus in VM, and also affects the diversity of 
microbes. Age, menstruation, hormone levels, intercourse, other lifestyle 
habits like smoking, hygiene have an impact on the bacterial community 
of a woman [33, 34]. The description of the VM in different stages in a 
woman’s life is multifaceted [35]. 
The dramatic change in VM could be noted at the time of puberty 
when hormone (estrogen) and glycogen levels increase [36]. The 
increased level of estrogen and glycogen facilitates or promote the 
growth of Lactobacillus, and it is known that the high level of 
glycogen is maintained during the fertile period of a woman and 
further decline in its level during menopause. Lactobacillus protects 
the vaginal area from pathogenic colonization by creating the acidic 
microenvironment, but an overgrowth of microaerophilic bacteria 
cause distress, itching, and foul-smelling discharge [37, 38]. Several 
studies suggested that diversity of Lactobacillus spp. and its richness 
has been decreased during or after menopause [36]. 
Probiotics and menopause 
The postmenopausal women with the significantly high Nugent 
score (between 4 to 6) were screened and selected for the study. 
The Nugent scoring is an unbiased, semi-quantitative evaluation 
(microbial content) of vaginal secretion. The subjects were 
randomly divided into two groups and supplemented with either 
probiotic (lyophilized L. reuteri RC-14 and L. rhamnosus GR-1 along 
with sodium alginate; 2.5 × 109
About 2044 women (40-65 y) were supplemented with a mixture of 
soybean extract (contains genistein and daidzein; 30 mg each), L. 
sporogenes (500 million spores), 5 µg of vitamin D and 141 mg of 
calcium for six months and the changes in climacteric symptoms 
were assessed by questionnaire. The changes were noted by 
gynecologists and self-assessment. The results suggested that the 
soybean extract with probiotic supplementation significantly 
improved the climacteric symptoms and sexuality [40]. 
 CFU each) or placebo (lactose) for 
fourteen days. After the intervention, vaginal swabs were collected 
and further subjected to Nugent scoring. The results showed that 
about 60% of women who received probiotic supplement had a 
reduction in their Nugent score from the baseline when compared to 
that of the placebo group. About three grade reduction was observed 
among the probiotic group, which indicates the significant 
improvement in the host health. The results suggested that the oral 
supplementation of probiotics help to restore the normal flora of the 
vagina [39]. 
A double-blind, randomized, placebo-controlled study was conducted 
with postmenopausal women with vaginal atrophy symptoms to know 
the impact of supplementation of Gynoflor® vaginal tablets (a blend of L. 
acidophilus KS400 and estriol 0.03 mg). The supplement was provided 
for 12 d for initial treatment and 2 tablets per week for 12 w to maintain 
the effects. Vaginal maturation index (VMI) was changed positively in the 
treatment group (35.2%) when compared to placebo (9.9%). The study 
proved that Gynoflor® is effective in reducing vaginal atrophy 
symptoms and improved the VMI [41]. 
The ovariectomized mouse was supplemented with L. reuteri ATCC 
PTA 6475 via oral gavage (1×109 CFU/ml trice per day) and through 
drinking water (1.5×108 CFU/ml) for four weeks. The probiotic 
supplementation significantly reduced the bone resorption and 
osteoclastogenesis. The increase in CD4+
Postmenopausal breast cancer patients receiving chemotherapy (with 
vaginal atrophy and altered microbiota) were treated with probiotics (a 
mixture of 1 × 10
T-lymphocytes has been 
reduced and thereby L. reuteri directly repressed osteoclastogenesis, 
and probiotic intervention altered the gut microbiome of the 
experimental mouse, especially Clostridiales was increased in the 
treated mouse. The results suggested that supplementation of L. 
reuteri suppress the post-menopausal bone loss [42]. 
Symptomatic postmenopausal women were treated with probiotic 
(B. breve B3 ATCC 15700; 1 trillion CFU) and nutraceutical formula 
(80 mg of soy isoflavones, 50 mg of Angelica sinensis extract, 200 mg 
of Morus alba leaf extract, and 56.25 mg of magnesium) for 4 w or 
probiotic and placebo or vice versa. The menopause rating scale 
(MRS) score was reduced, and a significant reduction in 
triglycerides, LDL, and increase in HDL was observed in the 
probiotic-treated group. The intervention of probiotic and 
nutraceutical formula improved the MRS score and risk of 
cardiovascular diseases [43]. Peri-menopausal women subjects were 
supplemented with isoflavones and probiotics (34 mg/d isoflavones; 
probiotic combinations and dosage were not revealed in the study) 
for 12 w. The hot flush frequency (HFF), hot flush intensity, self-
reported HFF, and hot flush severity, plasma lipids and blood 
pressure were measured. The results suggested that moderate 
intervention of red clover isoflavone and probiotics significantly 
reduced the self-reported vasomotor symptoms [44]. 
9 CFU of L. crispatus LbV 88, 1 × 109CFU of L. rhamnosus 
LbV 96, 0.2 × 109 CFU of L. ensenii LbV 116 and 0.3 × 109
 
CFU of L. gasseri 
LbV 150N) twice daily for two weeks. After treatment, changes in the 
vaginal microbiota and Nugent score were reexamined and compared 
with baseline. The results suggested that probiotic intervention 
significantly reduced the Nugent score in the probiotic-treated group 
when compared to that of the placebo. The vaginal microbiota also 
altered positively in probiotic-treated women. The study proved that 
probiotic supplementation helps to regain the normal vaginal flora in 
women receiving chemotherapy for cancer [45]. 
Table 1: The influence of probiotic supplementation on the consequences of menopause 
S. 
No. 
Subjects Intervention Dose Duration Findings Ref. 
1 Postmenopausal women 
(72 subjects) 
L. rhamnosus GR-1 and L. 
reuteri RC-14 
2.5 × 109 14 d  CFU 
each 
Nugent score was reduced, and 
health status improved 
significantly. 
[39] 
2 Women (2044 subjects) Soy extract (genistein and 
daidzein; 30 mg each),  
L. sporogenes, calcium (141 




6 mo Improved the climacteric 
symptoms and sexuality 
[40] 
3 Postmenopausal women 
with vaginal atrophy 
L. acidophilus KS400 and 
estriol 0.03 mg (Gynoflor®) 
- Single tablet for 
12 d followed by 
Gynoflor ® improved VMI after 
the 12-day initial therapy, and 
[41] 
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symptoms 2 tablets per 
week for 12 w 
two tablets weekly was 
appropriate to prevent the 
relapse. 
4 Balb/c mice 
ovariectomized MP 
model 
L. reuteri ATCC PTA 6475 1×10







Trice per day for 
4 w 
Significantly protected mice from  




5 Postmenopausal women 
(43 subjects) 
B. breve B3 ATCC 15700, 
nutraceutic preparation 
1 trillion CFU 4 w Menopause rating scale score 




women (62 subjects) 
A mixture of probiotic LAB 34 mg/d 
isoflavones and 
probiotics 
12 w Suppressed the self-reported 
vasomotor symptoms 
[44] 
7 Postmenopausal breast 
cancer patients 
L. crispatus LbV 88, L. 
rhamnosus LbV 96, L. ensenii 
LbV 116 and L. gasseri LbV 
150N 
2.5 × 109 2 w CFU in 
total 
Reduction in Nugent score, 




Generally, probiotic supplementation improved the health status of 
gastrointestinal (GI) system, and it has been proved by several 
clinical and human studies. Recently, the health benefits of probiotic 
were beyond the GI and its associated system such as anti-aging, 
anti-inflammation, improved the cognitive decline, anti-
hypertension, anti-hypercholesterolemia, etc. The role of probiotic 
to manage the postmenopausal disorders and to control the 
climacteric symptoms is the recent subject of interest for several 
researchers [46]. The well-planned, placebo-controlled clinical 
studies on the health benefits of probiotics in menopausal women 
are very limited (table 1). The reports clearly suggested that the 
intervention of optimum level of probiotic supplementation along 
with some nutraceuticals improved the climacteric symptoms and 
vaginal health status by altering the microbiota. Several studies 
recommend the isoflavones supplementation to treat symptoms of 
menopause. The combination of an enzyme producing probiotics 
such as β-glucosidase producing probiotics with soy extract help to 
improve the symptoms of menopause via producing bioactive 
isoflavone aglycones [47]. A study reported that the fermentation of 
soy milk with L. acidophilus does not significantly increase the 
absorption of Ca in osteopenic post-menopausal women [48]. Some 
controversial reports stated that the supplementation of soy-
isoflavone does not influence the microbiota of menopausal women 
[49]. The mechanism of probiotics mediated health improvement in 
menopausal women is not yet explained clearly. The connection 
between probiotic, gut microbiota, vaginal microbiota, and hormone 
(estrogen) deficit are the subject of several controversies. Further 
detailed well-planned intensive studies are required to explore the 
mysteries between the probiotics and menopause.  
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